The EU has given Gilead the green light to market its twice-yearly pre-exposure prophylaxis (PrEP) product lenacapavir, which ...

Analysts and charities have identified Gilead’s new HIV prevention injection as key to curbing infection rates ...

The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV ...

Gilead Sciences (NASDAQ:GILD) said Tuesday it has received European Commission (EC) approval for its twice-yearly injection to prevent HIV, a key regulatory milestone following its U.S. clearance ...

While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an ...

Kite Pharma will buy Interius BioTherapeutics for $350 million in cash to add an in vivo CAR‑T platform that creates T‑cell ...

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

CVS is opting against covering a twice-yearly injectable HIV prevention drug, drawing criticism from advocates who are ...

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 ...

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...